Most HEOR teams discover the weaknesses in their evidence package at the worst possible moment: during the HTA body review, when a NICE technical team issues a clarification request about an indirect treatment comparison methodology, or when a G-BA hearing reveals that the ZVT comparator framing was not adequately justified, or when a JCA assessment team challenges the patient-relevance of the primary endpoint. By that point, the submission is filed, the clock is running, and the team is responding under time pressure rather than acting on advance intelligence.[3]
The question every HEOR and market access team should be able to answer before submission is: what would a NICE assessor, a G-BA scientific reviewer, or an ICER analyst actually challenge in this dossier? Answering that question accurately requires either access to HTA body experts before submission, which is expensive, limited, and not always available at the depth needed, or a systematic way to simulate how those experts would read and challenge the evidence. KnolPersona, the AI expert intelligence and evidence stress-testing module within our Knolens platform, is built to answer exactly that question at scale, before the submission clock starts.[3]
1. The Problem KnolPersona Solves: The Blind Spot Before Submission
Every HEOR team building a submission dossier faces a structural challenge: they are too close to the evidence to identify the challenges that an external reviewer with no prior investment in the work will immediately spot. The team has spent months or years assembling the evidence base. They know every study, every data point, and every methodological decision. This depth of knowledge is an asset for building the dossier. It is a liability for identifying the reviewable weaknesses in it.[4]
The HTA submission landscape in 2026 has made this problem more acute. The EU JCA, mandatory for oncology and ATMP products from January 2025, gives manufacturers just three months between PICO finalisation and the dossier submission deadline. That is three months to build a complete clinical dossier, generate ITC analyses, prepare evidence tables, and identify and address the vulnerabilities that assessors will challenge. With NICE, G-BA, HAS, and ICER each applying different evidence standards and scrutinising different aspects of the same evidence package, the volume of potential challenges is large and the time to address them is limited.
KnolPersona compresses the pre-submission review cycle by simulating the expert perspective of each HTA body reviewer, identifying the specific challenges they are most likely to raise, and generating the evidence-grounded response frameworks the team needs to address those challenges before submission rather than after.
2. What AI Expert Intelligence Actually Means
The term AI expert intelligence describes a specific capability: an AI system that has internalised the methodology, precedent decisions, evidence standards, and reasoning patterns of a specific expert domain, and can apply that knowledge to generate expert-level analytical perspectives on new evidence submissions.
KnolPersona builds expert intelligence by drawing on the Knolens knowledge graph's structured repository of HTA precedent decisions. Every NICE appraisal, G-BA benefit assessment, HAS SMR/ASMR decision, and ICER evidence report in the knowledge layer carries structured metadata: the evidence challenges raised, the comparator definitions applied, the endpoint patient-relevance judgements made, the ITC methodologies accepted or rejected, and the specific language used in each conclusion.Across hundreds of prior assessments for analogous products in the same indication and mechanism class, patterns emerge that define what each HTA body's expert reviewers look for, what they challenge, and what evidence they find persuasive.
KnolPersona applies this structured pattern knowledge to a new evidence submission. Given a dossier clinical section, a protocol design document, or an evidence architecture specification, KnolPersona generates a structured assessor challenge report: the specific questions a NICE technical team is most likely to raise, the ZVT justification issues a G-BA scientific reviewer is most likely to identify, and the evidence quality concerns an ICER analyst is most likely to document. Every challenge is grounded in documented precedent from the knowledge base, not a generic assessment of evidence quality
3. Five Expert Perspectives KnolPersona Can Simulate
KnolPersona is not limited to HTA body simulation. The expert perspectives most valuable to pharma HEOR, clinical, and market access teams span five distinct domains. [4]
HTA Body Assessors: KnolPersona simulates the review perspectives of NICE technical teams, G-BA scientific advisors, HAS clinical assessment panels, and ICER evidence report teams. For each body, the simulation draws on the structured precedent knowledge of that body's historical assessment behaviour: what evidence they have accepted, what they have challenged, and what methodological standards they consistently apply. The output is an assessor challenge report specific to each body, giving the HEOR team a structured view of the submission's vulnerabilities from each relevant HTA perspective before it is filed.
Regulatory Reviewers: For regulatory submission documents, KnolPersona simulates the perspective of FDA and EMA scientific reviewers, identifying the evidence gaps, statistical methodology concerns, and patient population characterisation issues that regulatory reviewers are likely to raise based on precedent review decisions for analogous products. For teams preparing both a regulatory submission and an HTA dossier from the same evidence base, the regulatory simulation runs in parallel with the HTA simulation, identifying any tension between the evidence framing that regulatory and HTA reviewers each need
Payer Negotiators: KnolPersona simulates the perspective of commercial payer decision-makers in the US, Germany, France, and the UK, identifying the value evidence gaps that will drive reimbursement hesitation and the specific data points that payers will use to challenge the product's value positioning. For market access teams preparing for payer meetings and formulary negotiations, this simulation transforms the pre-meeting preparation from a general evidence review to a targeted vulnerability assessment.
Clinical Opinion Leaders: KnolPersona simulates the perspective of key opinion leaders in the relevant therapeutic area, identifying the clinical practice concerns that KOLs are likely to raise about the evidence: whether the trial population reflects real-world clinical practice, whether the comparator represents the current standard of care, and whether the endpoints capture the outcomes that clinicians consider meaningful.
Statistical Reviewers: For submissions involving network meta-analyses, indirect treatment comparisons, and survival extrapolation models, KnolPersona simulates the perspective of a biostatistics reviewer, identifying the methodology documentation gaps, heterogeneity characterisation limitations, and sensitivity analysis omissions that statistical reviewers routinely identify in dossier technical submissions.
4. How KnolPersona Generates the Assessor Challenge Report
The KnolPersona challenge report generation process operates in three stages, each building on the Knolens knowledge graph infrastructure.[9]
Stage 1, Evidence submission ingestion: The HEOR team submits the evidence package, protocol document, or dossier clinical section to KnolPersona. This can be a complete dossier section, a Phase III protocol, an evidence architecture specification, or an ITC analysis document. KnolPersona processes the evidence against the knowledge layer for the indication and mechanism class.
Stage 2, Precedent pattern matching: KnolPersona queries the Knolens knowledge graph for all prior assessments of analogous products by the target HTA body. It identifies the pattern of challenges raised across those assessments: which aspects of the evidence were consistently questioned, which comparator definitions were applied, which endpoint patient-relevance standards were used, and which ITC methodologies were accepted or rejected. These patterns define the expert reviewer's likely perspective on the new submission.
Stage 3, Challenge report generation: KnolPersona generates a structured assessor challenge report. Each challenge is presented in the format a real HTA reviewer would use: the specific aspect of the submission being challenged, the methodological standard it falls short of, the precedent from prior assessments that grounds the challenge, and the evidence action the team should take to address it before submission. Challenge reports are generated separately for each target HTA body, with body-specific language and methodology framing.
5. The Pre-Submission Protocol Review: KnolPersona in Phase II
The highest-value application of KnolPersona is not the pre-submission dossier review. It is the Phase II protocol review, where KnolPersona's assessor simulation identifies the evidence of vulnerabilities in a proposed Phase III trial design before the protocol is locked. Evidence problems identified at this stage can be corrected. Evidence problems identified at HTA submission cannot.
The Phase II protocol review workflow: the clinical team shares the proposed Phase III protocol with KnolPersona. The simulation analyses the protocol against the evidence standards of the target HTA bodies, identifies the comparator alignment gaps, endpoint patient-relevance concerns, subgroup pre-specification omissions, and ITC feasibility issues that will create vulnerabilities at submission, and generates a structured protocol adjustment report. Each identified issue comes with a specific evidence action: which subgroup analyses to pre-specify, which endpoints to add as secondary measures, which comparator justification documentation to build into the protocol
For products entering Phase III today with JCA submissions required at the time of EMA application, this Phase II review is not optional. The three-month JCA submission window, combined with the complexity of simultaneous multi-HTA dossier preparation, leaves no time to address fundamental evidence architecture problems that could have been corrected at protocol stage. KnolPersona makes this advance review systematic, not dependent on the availability of individual HTA expert consultants who may have limited capacity and inconsistent precedent knowledge across multiple HTA bodies simultaneously
6. KnolPersona and the ISPOR ELEVATE-GenAI Framework
In 2025, the ISPOR Working Group on Generative AI published the ELEVATE-GenAI framework, a set of reporting guidelines specifically designed for HEOR studies using large language models. The framework covers ten domains including model characteristics, accuracy, reproducibility, and fairness and bias, providing the structured reporting standard that HEOR professionals need to use AI tools in ways that satisfy HTA body and peer review requirements. [1]
KnolPersona's design aligns with the ELEVATE-GenAI framework's core requirements. The challenge reports KnolPersona generates are grounded in sourced precedent from the Knolens knowledge base, not in LLM-generated approximations of what HTA reviewers might say. Every challenge is attributed to specific prior assessments that document the HTA body's actual behaviour. The methodology is transparent and reproducible. Human expert review is integrated into the workflow before any KnolPersona output influences a protocol decision or a dossier submission. These are not just aspirational qualities. They are architectural properties of the KnolPersona system that allow our clients to document ELEVATE-GenAI compliance for any HEOR workflow that includes KnolPersona as an evidence stress-testing component.
7. The Reviewer Query Response Accelerator
KnolPersona's simulation capability does not end at the pre-submission stage. It continues to deliver value throughout the HTA review process, specifically in the query response phase when HTA bodies issue formal clarification requests.
NICE issues formal clarification questions approximately four weeks after submission. G-BA requests hearing attendance within twelve weeks. ICER may issue public comment periods at any point in its review. For a HEOR team managing simultaneous multi-HTA submissions, responding to concurrent queries from multiple bodies, each framed in that body's methodological language, under tight deadlines, is one of the highest-pressure phases of the market access process.
KnolPersona supports query response generation by retrieving the relevant evidence module from the Knolens knowledge layer and generating the response in the requesting body's required format with full source attribution. Because KnolPersona has already simulated the reviewer's perspective before submission, the team has typically pre-built the evidence arguments that the query requires. The response cycle compresses from weeks to days, and the factual consistency of responses across bodies is maintained automatically by the shared evidence layer that underpins all KnolPersona outputs.
8. Real-World Impact: What Changes When Teams Use KnolPersona
The practical impact of KnolPersona on HEOR and market access team performance shows up in three measurable dimensions
Fewer post-submission clarification requests: Teams that run KnolPersona challenge reports before submission consistently identify and address the evidence of vulnerabilities that would otherwise generate NICE technical queries and G-BA hearing questions. The clarification request rate falls because the challenges have already been answered in the submission.
Faster response cycles when queries do arrive: Because KnolPersona has already modelled the reviewer's perspective and the Knolens knowledge layer contains the evidence base for every response, query responses are generated in hours rather than weeks. The team arrives at a query response discussion with a pre-structured evidence argument, not an evidence reconstruction task.
More defensible protocol designs: Clinical teams that use KnolPersona for Phase II protocol review consistently produce protocols with stronger HTA alignment: better comparator justification, more comprehensive subgroup pre-specification, and more defensible endpoint patient-relevance rationale. The evidence problems that KnolPersona identifies at protocol stage are corrected before Phase III locks them in.
These outcomes reflect the core value proposition of KnolPersona: it shifts the HEOR team's relationship with HTA body challenges from reactive response to proactive preparation. The assessor's perspective is available before the assessor has seen the submission.
9. How Fast Can Your Team Start Using KnolPersona?
KnolPersona is a module within the Knolens platform, activated alongside KnolAI and the Knolens knowledge layer. There is no standalone implementation. When your team onboards to Knolens, KnolPersona is available from Sprint 1 alongside the full evidence research capability of KnolAI and the authoring capability of KnolComposer.
Sprint 1, Weeks 1 to 2, First challenge report live: Your indication scope and target HTA bodies are configured. KnolPersona runs the first assessor challenge report against an existing evidence document, protocol, or dossier section. The output is a structured challenge report identifying the vulnerabilities in the current evidence package from the perspective of each target HTA body, grounded in sourced precedent from the Knolens knowledge graph. Your team sees the assessor's perspective on the current evidence state within days of onboarding.
Sprint 2, Weeks 3 to 4, Protocol review workflow and multi-body simulation activated: KnolPersona is configured for your Phase III protocol review workflow. The simulation covers all target HTA bodies simultaneously, generating body-specific challenge reports in parallel. The protocol adjustment report identifies the specific evidence actions required to address each identified vulnerability before protocol lock.
Sprint 3, Weeks 5 to 6, Query response framework configured: KnolPersona's query response generation is configured for your submission scope. Pre-built response frameworks for the most likely query categories from each target HTA body are activated. When queries arrive post-submission, response generation runs from the same knowledge layer that powered the pre-submission challenge report, with full factual consistency across bodies.[6]
Conclusion
The gap between what HEOR teams believe their evidence demonstrates and what HTA body reviewers actually challenge in it is one of the most consequential information gaps in pharmaceutical market access. KnolPersona, our AI expert intelligence module within Knolens, Pienomial’s AI research platform, closes that gap systematically and repeatably.
By simulating the evidence review perspectives of NICE, G-BA, HAS, ICER, and payer decision-makers before the submission is filed, KnolPersona gives HEOR and market access teams the advance intelligence they need to strengthen their evidence architecture, address vulnerabilities proactively, and arrive at HTA review with a submission that is already built to withstand the challenges it will receive. At Pienomial, we built KnolPersona because we believe the best time to respond to a NICE clarification request is before it is sent.
CTA: See KnolPersona in action. Book a demo with the Pienomial team today.
